# A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

> **NCT02658825** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-63623872 2400 milligram (mg)
- **DRUG:** JNJ-63623872 3000 mg
- **DRUG:** JNJ-63623872
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo (Matching with JNJ-63623872 2400 mg)
- **DRUG:** Placebo (Matching with JNJ-63623872 3000 mg)
- **DRUG:** Placebo (Matching with JNJ-63623872 Dose)
- **DRUG:** Placebo (Matching with Moxifloxacin)

## Key facts

- **NCT ID:** NCT02658825
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658825, "A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02658825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*